培门冬酶联合GEMOX方案治疗初治鼻腔NK／T细胞淋巴瘤临床疗效观察  

Clinical efficacy of pegaspargase plus GEMOX regimen for initial treatment of nasal NK/T-cell lymphoma

作　　者：梁绍平[1] 王华庆[1] 张会来[1] 钱正子[1] 周世勇[1] 赵静[1] 刘霞[1] 

机构地区：[1]天津医科大学肿瘤医院淋巴瘤内科、国家肿瘤临床医学研究中心、天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2014年第19期1225-1228,共4页Chinese Journal of Clinical Oncology

摘　　要：目的：观察培门冬酶联合GEMOX方案治疗初治鼻腔NK/T细胞淋巴瘤的临床疗效及安全性。方法：分析2011年6月至2012年3月间天津医科大学肿瘤医院收治的初治鼻腔NK/T细胞淋巴瘤12例，采用P-GEMOX治疗，具体剂量为吉西他滨800～1000 mg/m^2，d1，8；奥沙利铂130 mg/m^2，d1；培门冬酶2500 IU/m^2，d2，每21天为1个周期。评价疗效及不良反应。结果：12例患者中1例出现急性胰腺炎退出治疗，余11例在接受P-GEMOX方案2个周期治疗后，完全缓解（CR）1例，部分缓解（PR）7例，疾病稳定（SD）2例，疾病进展（PD）1例，客观有效率（ORR）为72.7%，疾病控制率（DCR）为90.9%。全组患者2年总生存（OS）率达90.9%。11例患者接受中位6个周期的P-GEMOX方案化疗，不良反应发生率为81.8%，7例患者出现骨髓抑制（63.6%），5例患者出现转氨酶升高（45.5%），4例患者出现恶心呕吐（36.4%），2例患者出现凝血因子异常（18.2%），无一例患者出现严重过敏反应、血栓形成及血糖异常。结论：培门冬酶联合GEMOX方案治疗初治鼻腔NK/T细胞淋巴瘤疗效好，但不良反应发生率较高。Objective：To evaluate the efficacy and safety of pegaspargase plus GEMOX （pegaspargase, gemcitabine, oxaliplatin） regimen in the initial treatment of nasal NK/T-cell lymphoma. Methods： Twelve preliminarily diagnosed nasal NK/T-cell lymphoma patients in Tianjin Medical University Cancer Institute and Hospital from June 2011 to March 2012 were analyzed. All patients took the pegaspargase plus GEMOX regimen （gemcitabine 800-1 000 mg/m^2 on days 1 and 8, oxaliplatin 130 mg/m^2 on day 1, and pegaspargase 2 500 IU/m^2 on day 2）, every three weeks for one cycle. The efficacy and toxicity of the regimen were evaluated in the follow-up treatment. Results：After two cycle treatments, 1 patient dropped out of treatment because of acute pancreatitis;the remaining 11 patients had response, in which 1 achieved complete response , 7 had partial response, 2 had stable disease, and 1 had progressive disease. The objective response rate was 72.7%, and the disease control rate was 90.9%. The 2-year overall survival rate was 90.9%. With median 6-cycle P-GEMOX regimen treatment, 81.8% of 11 patients presented side effects, primarily myelosuppression and hepatic dysfunction. Conclusion：Pegaspargase plus GEMOX regimen showed high efficacy on the initial treatment of nasal NK/T-cell lymphoma patients, but the incidence of adverse effect was still high.

关 键 词：培门冬酶 吉西他滨 奥沙利铂 NK/T细胞淋巴瘤 初治 

分 类 号：R739.62[医药卫生—肿瘤]